Australia, Jan. 8 -- Bicycletx Ltd., owns the trademark (2490962) for 'B' and 'LTR B,NOTCHED' till Aug. 27, 2034.
Status: protected:
Registered/protected
Classes: 5 [Pharmaceuticals; pharmaceutical preparations; pharmaceutical products; pharmaceutical products and preparations for use in relation to oncology; pharmaceutical products and preparations for use in relation to ophthalmology; pharmaceutical products and preparations for use in relation to neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and/or prevention of respiratory disease; pharmaceutical products and preparations for the treatment and/or prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and/or prevention of metabolic disease; pharmaceutical products and preparations for the treatment and/or prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging; pharmaceutical products and preparations for the treatment and/or prevention of renal disease; pharmaceutical products and preparations for the treatment and/or prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and/or prevention of muscular skeletal disease.], 42 [Scientific and technological services and research and design relating thereto; industrial analysis and research services; pharmaceutical research and development services; medical research and development services; pharmaceutical testing and clinical trials; medical testing and clinical trials; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; information consultancy and advisory services relating to the aforesaid.] and 44 [Medical services; healthcare services; pharmaceutical services; medical consulting services; advisory services relating to pharmaceuticals; consultancy and information services relating to pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in connection with respiratory disease; medical services in connection with cardiovascular disease; medical services in connection with metabolic disease; medical services in connection with the treatment and/or prevention of viral infections; medical services in connection with diagnostics and imaging; medical services in connection with renal disease; medical services in connection with gastrointestinal disease; medical services in connection with muscular skeletal disease; pharmaceutical services in the field of oncology; pharmaceutical services in the field of ophthalmology; pharmaceutical services in the field of neurology; pharmaceutical services in the field of anti-infectives; pharmaceutical services in connection with respiratory disease; pharmaceutical services in connection with cardiovascular disease; pharmaceutical services in connection with metabolic disease; pharmaceutical services in connection with the treatment and/or prevention of viral infections; pharmaceutical services in connection with diagnostics and imaging; pharmaceutical services in connection with renal disease; pharmaceutical services in connection with gastrointestinal disease; pharmaceutical services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid.]
Type of Mark: Figurative
Date of Acceptance: Oct. 22, 2024
Registration Advertised: Jan. 7
For further details contact J A Kemp LLP .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2490962.
Disclaimer: Curated by HT Syndication.
